Laquinimod

Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis
Wegner C, Stadelmann C, Pförtner R, Raymond E, Feigelson S, Alon R, Timan B, Hayardeny L, Brück W. J Neuroimmunol. 2010 Oct 8; 227(1-2):133-43.

Oral laquinimod therapy in relapsing multiple sclerosis
Preiningerova J, Yale Multiple Sclerosis Center, US. Expert Opin. Investig. Drugs (2009) 18(7) pages 985-989. http://informahealthcare.com/doi/pdf/10.1517/13543780903044944

Effect of Laquinimod on MRI-monitored disease activity in patients with RRMS: a multicenter, randomized, double-blind, placebo-controlled phase IIb study
Comi G, Pulizzi A, Rovaris M, Abramsky O, Arbizu T, Boiko A, Gold R, Havrdova E, Komoly S, Selmaj KW, Sharrack B, Filippi M. The Lancet 2008, Volume 371, Issue 9630: 2085 - 2092.

Development of a Practical and Reliable Synthesis of Laquinimod
Wennerberg J, Björk A, Fristedt T, Granquist B, Jansson K, Thuvesson I. Organic Process Research & Development 2007, 11, 674-680.

Determination of the immunomodulator laquinimod in human plasma by liquid chromatography/tandem mass spectrometry; development, validation and application of two methods in clinical pharmacokinetic profiling.
Sennbro CJ, Olin M, Edman K, Hansson G, Gunnarsson PO and Svensson LD. Rapid Communications in Mass Spectrometry, 2006; 20:3313-3318.

Inhibition of the development of chronic experimental autoimmune encephalomyelitis by laquinimod (ABR-215062) in IFN-h k.o. and and wild type mice.
Runström A, Leanderson T, Ohlsson L, Axelsson B. Journal of Neuroimmunology 173 (2006) 69-78.

Treatment with laquinimod reduces development of active MRI lesions in relapsing multiple sclerosis.
Polman C, Barkhof F, Sandberg-Wollheim M, Linde A, Nordle O & Nederman T. Neurology 64; 2005, 987-991.

The new orally active immunoregulator Laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Brunmark C, Runström A, Ohlsson L, Sparre B, Brodin T, Åström M & Hedlund G. J Neuroimmunol. 130; 2002, 163-172.

Supression of experimental autoimmune neuritis by ABR-215062 is associated with altered Th1/Th1 balance and inhibited migration of inflammatory cells into the peripheral nerve tissue.
Zou L-P, Abbas N, Volkmann I, Nennesmo I, Levi M, Wahren B, Winblad B, Hedlund G & Zhu J. Neuropharmacol. 42; 2002, 731-739.

Determination of laquinimod in plasma by coupled-column liquid chromatography with ultraviolet absorbance detection.
Edman K, Eriksson B, Svensson L & Gunnarsson PO. J Chromatogr. B 785; 2003, 311-316.

Synthesis and biological evaluation of new 1,2-dihydroxo-4-hydroxy-2-oxo-3-quinoline carboxamides for treatment of autoimmune disorders: Structure-activity relationship.
Jönsson S, Andersson G, Fex T, Fristedt T, Hedlund G, Jansson K,Abramo L, Fritzon I, Pekarski O, Runström A, Sandin H, Thuvesson I& Björk A. J. Med. Chem. 47; 2004, 2075-2088.

Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-b in Lewis rats.
Yang J-S, Xu L-Y, Xiao B-G, Hedlund G & Link H. J Neuroimmunol 156; 2004, 3-9.

Posters

48-week open safety study with a high dose oral laquinimod in MS patients.
Sandberg-Wollheim M, Nederman T, Linde A.
Poster presentation at ECTRIMS 05, Thessaloniki, Sep 28-Oct 1, 2005.

The Orally Active Immunomodulator Laquinimod Inhibits Development of MurineExperimental Autoimmune Encephalomyelitis (EAE) in IFN--/- and in WildType Mice.
Leanderson T, Runstrom A, Ohlsson L, Nederman T & Axelsson B.
Poster presentation, AAN, San Fransisco, Apr 26 – 29, 2004.

Pharmacokinetic evaluation in the study: A double blind, randomised, phase II study of oral laquinimod versus placebo in patients with relapsing Multiple Sclerosis.
Nordle O, Sparre B, Linde A, Nederman T, Gunnarsson PO.
Poster presentation at ECTRIMS 04,Vienna, Oct 6-9, 2004.

The new orally active immunoregulator ABR-215062 effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Runström A, Brunmark C, Ohlsson L, Sparre B & Hedlund G.
Poster presentation (IV-12), Bezon Symposium No 49 MultipleSclerosis: Genetics, pathogenetics and Therapy, Copenhagen, Aug 18 –22, 2002.

The new orally active immunoregulator laquinimod (ABR-215062) effectively inhibits development and relapses of experimental autoimmune encephalomyelitis.
Runström A, Brunmark C, Ohlsson L, Sparre B, Axelsson B & Hedlund G.
Poster presentation, Medicon Valley Academy, Malmo, Oct 8 – 10, 2002.

Laquinimod (ABR-215062) a candidate drug for treatment of Multiple Sclerosis inhibits the development of experimental autoimmune encephalomyelitis in IFN-β knock-out mice.
Runström A, Axelsson B, Hedlund G, Nederman T & Leandersson T.
Poster presentation, Medicon Valley Academy, Malmo, Oct 8 – 10, 2002.

Pharmacokinetically guided design of a repeat dose safety and tolerance study of laquinimod in Healthy Volunteers.
Sparre B, Ellman M, Nordle Ö, Olin M, Höglund P & Gunnarsson PO.
Poster presentation, Medicon Valley Academy, Malmo, Oct 8 – 10, 2002.

Laquinimod, a candidate drug for oral treatment of MS, with improved therapeutic window, compared to the predecessor roquinimex, predicted for man.
Nederman T, Runström A, Cort N & Sparre B.
Poster presentation, Medicon Valley Academy, Malmo, Oct 8 – 10, 2002.

Linomide publications

Linomide in relapsing and secondary progressive MS.
Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC et al. Part I: Trial design and clinical results. Neurology 2000, 54; 1726-1733.

Linomide in relapsing and secondary progressive MS.
Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC et al. Part II: MRI results. Neurology 2000, 54; 1734-1741.

Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated Phase-III trials.
Tan IL, Lycklama á Nijeholt GJ, Polman CH, Adèr HJ, Barkhof F et al. Multiple Sclerosis 2000, 6; 99-104.

Low dose Linomide in type juvenile diabetes of recent onset, a randomised placebo-controlled double blind trial.
Countant R, Landais P, Rosilio M, Johnsen C, Lahlou N, Chaterlain P,Carel JC, Ludvigsson J, Boitard C, Bougnères PF. Diabetologia 1998, 41;1040-1046.

Treatment of secondary progressive multiple sclerosis with the immunomodulator Linomide: A double blind, placebo-controlled pilot study with monthly magnetic resonance imaging evaluation.
Karussis D.M, Meiner Z, Lehman D, Gomori J-M, Schwartz A, Linde A, Abramsky O. Neurology 1996, 47; 341-346.

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O, Lycke J, Tollesson PO, Svenningsson A, Runmarker B, Linde A, Åström M, Gjörstrup P, Ekholm S. Neurology 1996, 47; 895-900.